A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301)

PI: Dott. Giuseppe Lo Russo 

The goal of this clinical trial is to evaluate the efficacy and safety profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC. 

 Participants will be randomized 1:1 to 1 of the following 2 arms: 

• Arm 1 (experimental): dostarlimab plus belrestotug  

• Arm 2 (active comparator): pembrolizumab plus placebo